Instil Bio, Inc.
General ticker "TIL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $145.0M (TTM average)
Instil Bio, Inc. follows the US Stock Market performance with the rate: 19.2%.
Estimated limits based on current volatility of 3.4%: low 11.02$, high 11.80$
Factors to consider:
- Total employees count: 14 (-71.4%) as of 2024
- Top business risk factors: Operational and conduct risks, Significant losses, Regulatory and compliance, Market acceptance, Limited operating history
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [9.29$, 30.74$]
- 2025-12-31 to 2026-12-31 estimated range: [4.71$, 16.83$]
Financial Metrics affecting the TIL estimates:
- Negative: with PPE of -1.8 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -41.98 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 40.68 > -0.66
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of 64.29 > 63.39
- Negative: -0.75 < Inventory ratio change, % of 0
Short-term TIL quotes
Long-term TIL plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $226.46MM | $159.17MM | $73.54MM |
| Operating Income | $-226.46MM | $-159.17MM | $-73.54MM |
| Non-Operating Income | $1.21MM | $3.66MM | $2.26MM |
| Interest Expense | $1.88MM | $5.21MM | $8.99MM |
| R&D Expense | $141.06MM | $39.60MM | $21.84MM |
| Income(Loss) | $-225.25MM | $-155.51MM | $-71.28MM |
| Taxes | $-2.07MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $-223.18MM | $-156.09MM | $-74.14MM |
| Stockholders Equity | $363.61MM | $225.83MM | $169.44MM |
| Assets | $482.13MM | $325.63MM | $263.57MM |
| Operating Cash Flow | $-180.16MM | $-82.03MM | $-55.70MM |
| Capital expenditure | $84.59MM | $20.66MM | $10.00MM |
| Investing Cash Flow | $114.54MM | $41.13MM | $53.97MM |
| Financing Cash Flow | $71.89MM | $8.08MM | $1.75MM |
| Earnings Per Share** | $-34.46 | $-24.00 | $-11.39 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.